The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
about
Prediction of psilocybin response in healthy volunteersPharmacology of hallucinations: several mechanisms for one single symptom?Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical rolesHead-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model.Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens.To use or not to use: an update on licit and illicit ketamine useMystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of opennessLysergic acid diethylamide: a drug of 'use'?Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 yearsPharmacological treatment of anxiety disorders: current treatments and future directionsKetamine for treatment-resistant unipolar depression: current evidenceFluorine in psychedelic phenethylaminesKetamine decreases resting state functional network connectivity in healthy subjects: implications for antidepressant drug actionDecreased Thalamocortical Connectivity in Chronic Ketamine UsersPsychedelicsLSD-induced entropic brain activity predicts subsequent personality change.The imaginative mind.Looking for the Self: Phenomenology, Neurophysiology and Philosophical Significance of Drug-induced Ego Dissolution.Animal models of serotonergic psychedelics.Mismatch negativity encoding of prediction errors predicts S-ketamine-induced cognitive impairments.Neuromapping techniques in drug discovery: pharmacological MRI for the assessment of novel antipsychotics.Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.Alterations of consciousness and mystical-type experiences after acute LSD in humans.Glial GLT-1 blockade in infralimbic cortex as a new strategy to evoke rapid antidepressant-like effects in rats.Acute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects.Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies.Therapeutic infusions of ketamine: do the psychoactive effects matter?The alkaloids of Banisteriopsis caapi, the plant source of the Amazonian hallucinogen Ayahuasca, stimulate adult neurogenesis in vitro.The effects of subanesthetic ketamine infusions on motivation to quit and cue-induced craving in cocaine-dependent research volunteers.Modern neuroimaging in psychiatry: towards the integration of functional and molecular information.Psychedelic drug use in healthy individuals: A review of benefits, costs, and implications for drug policyPlant-based medicines for anxiety disorders, part 2: a review of clinical studies with supporting preclinical evidence.Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addictionReturn of the lysergamides. Part I: Analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD)Clinical applications of hallucinogens: A review.The natural hallucinogen 5-MeO-DMT, component of Ayahuasca, disrupts cortical function in rats: reversal by antipsychotic drugs.Tolerance and cross-tolerance to head twitch behavior elicited by phenethylamine- and tryptamine-derived hallucinogens in mice.Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction.Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission?Preliminary analysis of positive and negative syndrome scale in ketamine-associated psychosis in comparison with schizophrenia.
P2860
Q21134798-1223F492-06FB-4435-85BC-A8BF724C1D3EQ21284720-14BA07EE-BE8C-4197-BD93-F1509B84D69DQ22241778-6A633803-736D-4FD8-8C4E-6DBE703B6999Q24595389-EEA655A4-27A5-426F-B1F2-934C22F7B274Q24620764-92D1B514-0E6E-4C00-A395-06A235CBD42EQ24634006-7CDDA13B-5319-42A0-9052-4F0BC5EF4AA9Q24634013-1BBFF2C5-EEE3-42A6-A16B-008C615AB9A1Q26746133-5312567A-03C9-4F31-8F1F-A1CD46680530Q26746137-2134B508-7C38-4777-87E8-3446166E014CQ26851461-B5A8E14E-0D19-4644-9D01-DC250CC053D6Q27004508-F6146C49-0920-4B59-B129-31EEF6E82C0FQ28260924-7221D5F9-DD84-4092-9307-044FE4662ACFQ28484157-30F37EBD-A27E-45AA-9156-6FDC3F5E6122Q28555039-A72F95AD-53CD-418F-96E0-4422E69C3BEDQ30359998-555F72DC-021F-4BBF-94F8-D093E31E3E90Q30387757-FE6DBB6F-7D98-450D-B16E-D68E4212507EQ30390923-832FC34B-548F-4A1C-8AD8-AFE276161522Q30402789-6508A8BF-270B-492C-B579-4BC34A8BC932Q30444312-59EEE19A-0474-4C5A-93C7-4A798CE759CFQ30457813-8CC3D73F-6A97-47AD-B19C-D9840F1DEF13Q30564474-24089F65-2FF1-46BA-A8EF-8EBFEBCDC344Q30843010-8E8AE531-A0B2-4A2D-934C-8C319D4D9AD0Q30847957-AE40BF90-5499-4701-8DBC-BD77E37B6E17Q30852008-534C4B9D-9362-43D6-8190-36A4E320BE15Q33635662-2841C094-7B0B-4A62-998E-8B367501A9ABQ33693380-3ACD92DD-926F-4560-9CD2-14D8A55C70ABQ33880853-71C3B553-E108-4EF3-8854-F8F00C71D9CBQ33902992-1E5FDBAA-476E-47A2-B418-5844D81C0F99Q33926787-A3B41734-DA1A-4E27-8769-D9889D303920Q34015102-C4256C7A-4EE2-40FE-9847-BD4D3333AFEFQ34178760-7A703D03-1DC6-456B-A27C-443E457D91D2Q34343456-8D933C2D-1340-41E3-BA78-EAF3BE2E1E94Q34438146-4FB3C055-4924-4F1B-9127-C58DB537CBC6Q34497649-3336B7A4-52C9-4B74-8E42-3E3A23874D0EQ34535259-F8B8308A-6EA8-4E0A-B52E-740F11DAE1DEQ34660497-A5F5B317-8C8E-44C3-B096-0DB20459A39CQ35024752-C60EF183-FFC8-4CAB-BE21-715F29043EF0Q35126018-11993318-BCA9-42BE-9891-399365A22B06Q35225947-048EBC08-B19C-4BBB-9D88-2AAC96D0A365Q35653538-F30BF1CB-F467-48D0-8E93-9317F90ED7CF
P2860
The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
@ast
The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
@en
The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
@en-gb
The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
@nl
type
label
The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
@ast
The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
@en
The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
@en-gb
The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
@nl
prefLabel
The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
@ast
The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
@en
The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
@en-gb
The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
@nl
P3181
P356
P1476
The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
@en
P2093
Franz X. Vollenweider
Michael Kometer
P2888
P304
P3181
P356
10.1038/NRN2884
P407
P577
2010-08-18T00:00:00Z
P5875
P6179
1025657218